David A. Egan

8.2k citations

81 papers · 4.9k indexed · 3 hit papers · h-index 31

Impact in

Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
Molecular Biology top 2%
- Circular RNAs in diseases
- RNA Interference and Gene Delivery
- Signaling Pathways in Disease

Papers in ⓘ

Molecular Biology 50
- Receptor Mechanisms and Signaling 6
- Signaling Pathways in Disease 6
- Epigenetics and DNA Methylation 4
Oncology 16
- Cancer Cells and Metastasis 4
- Cancer-related Molecular Pathways 4

Co-authors: Reuven Agami (2 shared papers)Mariëtte Schrier (2 shared papers)Remco Nagel (2 shared papers)Carlos le Sage (2 shared papers)Ronald M. Evans (2 shared papers)Thomas F. Holzman (12 shared papers)Giulio Maira (1 shared paper)Neri Mercatelli (1 shared paper)
Journals: Journal of Medicinal Chemistry (8 papers)Biochemistry (5 papers)Assay and Drug Development Technologies (4 papers)Proceedings of the National Academy of Sciences (3 papers)SLAS DISCOVERY (3 papers)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

David A. Egan

81 papers receiving 4.8k citations

Hit Papers

align trajectories log scale

Intra-tumour diversification in colorectal cancer at the single-cell level 2018 · 376 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Nature
2008 Nature Cell Biology
2007 The EMBO Journal

Peers

Countries citing papers authored by David A. Egan

Since Specialization

Citations

This map shows the geographic impact of David A. Egan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Egan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Egan more than expected).

Fields of papers citing papers by David A. Egan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Egan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Egan. The network helps show where David A. Egan may publish in the future.

Co-authors

The 25 scholars most cited alongside David A. Egan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Egan Line = papers co-authored together David A. Egan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis Nature Cell Biology ·Qihong Huang, Kiranmai Gumireddy, Mariëtte Schrier, Carlos le Sage, Remco Nagel, Suresh Nair, David A. Egan, An‐Ping Li, Guanghua Huang, Andres J. Klein–Szanto, Phyllis A. Gimotty, Dionyssios Katsaros, George Coukos, Lin Zhang, Ellen Puré, Reuven Agami Hit paper breakdown →	2008	800
2	Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation The EMBO Journal ·Carlos le Sage, Remco Nagel, David A. Egan, Mariëtte Schrier, Elly Mesman, Annunziato Mangiola, C. Anile, Giulio Maira, Neri Mercatelli, Silvia Anna Ciafrè, Maria Giulia Farace, Reuven Agami Hit paper breakdown →	2007	651
3	Intra-tumour diversification in colorectal cancer at the single-cell level Nature ·Sophie Roerink, Nobuo Sasaki, Henry Lee-Six, Matthew D. Young, Ludmil B. Alexandrov, Sam Behjati, Thomas J. Mitchell, Sebastian Großmann, Howard Lightfoot, David A. Egan, Apollo Pronk, Niels Smakman, Joost van Gorp, Elizabeth Anderson, Stephen J. Gamble, Christopher Alder, Marc van de Wetering, Peter J. Campbell, Michael R. Stratton, Hans Clevers Hit paper breakdown →	2018	376
4	Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1 Nature ·Coenraad Kuijl, Nigel D. L. Savage, Marije Marsman, Adriaan W. Tuin, Lennert Janssen, David A. Egan, Mirjam Ketema, Rian van den Nieuwendijk, Susan J. F. van den Eeden, Annemieke Geluk, Alex J. Poot, Gijs van der Marel, Roderick L. Beijersbergen, Herman S. Overkleeft, Tom H. M. Ottenhoff, Jacques Neefjes	2007	256
5	Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening eLife ·Carla S. Veríssimo, René Overmeer, Bas Ponsioen, Jarno Drost, Sander Mertens, Ingrid Verlaan-Klink, Bastiaan van Gerwen, Marieke van der Ven, Marianne D. van de Wetering, David A. Egan, René Bernards, Hans Clevers, Johannes L. Bos, Hugo J.G. Snippert	2016	194
6	Kringle 5 of Human Plasminogen Induces Apoptosis of Endothelial and Tumor Cells through Surface-Expressed Glucose-Regulated Protein 78 Cancer Research ·Donald J. Davidson, Catherine J. Haskell, Sandy Majest, Abdullah Kherzai, David A. Egan, Karl A. Walter, Andrew J. Schneider, Earl Gubbins, Larry R. Solomon, Zhebo Chen, Rick Lesniewski, Jack Henkin	2005	194
7	Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation Proceedings of the National Academy of Sciences ·Harald M. H. G. Albers, Anping Dong, Laurens A. van Meeteren, David A. Egan, Manjula Sunkara, Erica W. van Tilburg, Karianne Schuurman, Olaf van Tellingen, Andrew J. Morris, Susan S. Smyth, Wouter H. Moolenaar, Huib Ovaa	2010	167
8	Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling Proceedings of the National Academy of Sciences ·Vassilis Doucas, Marc Tini, David A. Egan, Ronald M. Evans	1999	149
9	NMR studies of [U-13C] cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding Biochemistry ·Stephen W. Fesik, Robert T. Gampe, H. L. Eaton, Gerd Gemmecker, Edward T. Olejniczak, Placido Neri, Thomas F. Holzman, David A. Egan, Rohinton Edalji	1991	148
10	In vitro induction of alkaline phosphatase levels predicts in vivo bone forming capacity of human bone marrow stromal cells Stem Cell Research ·Henk‐Jan Prins, A. Koen Braat, Debby Gawlitta, Wouter J.A. Dhert, David A. Egan, Estel Tijssen-Slump, Huipin Yuan, Paul J. Coffer, Henk Rozemuller, Anton C. Martens	2013	130
11	NMR-Based Discovery of Lead Inhibitors That Block DNA Binding of the Human Papillomavirus E2 Protein Journal of Medicinal Chemistry ·Philip J. Hajduk, Jürgen Dinges, Gregory F. Miknis, Megan Merlock, Tim Middleton, Dale J. Kempf, David A. Egan, Karl A. Walter, Terry Robins, Suzy B. Shuker, Thomas F. Holzman, Stephen W. Fesik	1997	128
12	A Genome-wide Multidimensional RNAi Screen Reveals Pathways Controlling MHC Class II Antigen Presentation Cell ·Petra Paul, Tineke van den Hoorn, Marlieke L.M. Jongsma, Mark J. Bakker, Rutger C.C. Hengeveld, Lennert Janssen, Peter Cresswell, David A. Egan, S. Marieke van Ham, Anja ten Brinke, Huib Ovaa, Roderick L. Beijersbergen, Coenraad Kuijl, Jacques Neefjes	2011	115
13	Molecular genetics of acute promyelocytic leukemia Trends in Genetics ·Richard J. Lin, David A. Egan, Ronald M. Evans	1999	96
14	Isotope-Edited NMR of Cyclosporin a Bound to Cyclophilin: Evidence for a Trans 9,10 Amide Bond Science ·Stephen W. Fesik, Robert T. Gampe, Thomas F. Holzman, David A. Egan, Rohinton Edalji, Jay R. Luly, Robert L. Simmer, Rosalind Helfrich, Vimal Kishore, Daniel H. Rich	1990	92
15	Physiologically Relevant Metal Cofactor for Methionine Aminopeptidase-2 Is Manganese Biochemistry ·Jieyi Wang, George S. Sheppard, Pingping Lou, Megumi Kawai, Chang Park, David A. Egan, Andrew J. Schneider, Jennifer J. Bouska, Rick Lesniewski, Jack Henkin	2003	89
16	A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors Clinical Cancer Research ·Bastiaan Evers, Eva Schut, Eline van der Burg, Tanya M. Braumuller, David A. Egan, Henne Holstege, Pauline Edser, David J. Adams, Richard Wade‐Martins, Peter Bouwman, Jos Jonkers	2009	66
17	Discovery and Optimization of Boronic Acid Based Inhibitors of Autotaxin Journal of Medicinal Chemistry ·Harald M. H. G. Albers, Laurens A. van Meeteren, David A. Egan, Erica W. van Tilburg, Wouter H. Moolenaar, Huib Ovaa	2010	61
18	Solution Structure of the DNA-Binding Domain of a Human Papillomavirus E2 Protein: Evidence for Flexible DNA-Binding Regions Biochemistry ·Heng Liang, Andrew M. Petros, Robert Meadows, Ho Sup Yoon, David A. Egan, Karl A. Walter, Thomas F. Holzman, Terry Robins, Stephen W. Fesik	1996	55
19	Renin inhibitors. Dipeptide analogs of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency Journal of Medicinal Chemistry ·Jay R. Luly, Nwe Y. BaMaung, Jeff Soderquist, Anthony K. L. Fung, H. J. Stein, Hollis D. Kleinert, Patrick A. Marcotte, David A. Egan, Barbara A. Bopp	1988	53
20	Purification and characterization of the mammalian .beta.2-adrenergic receptor Biochemistry ·C J Homcy, Stanley G. Rockson, J L Countaway, David A. Egan	1983	53

About David A. Egan

David A. Egan is a scholar working on Molecular Biology, Oncology, Immunology, Cardiology and Cardiovascular Medicine and Cell Biology, having authored 81 papers that have together received 4.9k indexed citations. Recurring topics across this work include Cell Image Analysis Techniques (7 papers), Renin-Angiotensin System Studies (7 papers), Receptor Mechanisms and Signaling (6 papers), Signaling Pathways in Disease (6 papers), Epigenetics and DNA Methylation (4 papers), Cancer Cells and Metastasis (4 papers), Cancer-related Molecular Pathways (4 papers) and Toxin Mechanisms and Immunotoxins (4 papers). The work is most often cited by research in Cancer Research (1.6k citations), Molecular Biology (3.4k citations), Oncology (1.0k citations), Cell Biology (409 citations) and Immunology (517 citations). David A. Egan has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Reuven Agami, Mariëtte Schrier, Remco Nagel, Carlos le Sage, Ronald M. Evans, Thomas F. Holzman, Giulio Maira, Neri Mercatelli, Maria Giulia Farace and Silvia Anna Ciafrè. Their work appears in journals such as Journal of Medicinal Chemistry, Biochemistry, Assay and Drug Development Technologies, Proceedings of the National Academy of Sciences and SLAS DISCOVERY.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact